Stock Pick

3 ASX 200 shares to buy now: experts

Written by

openjargon

in

A male broker wearing a dark blue suit and tie puts his finger to his lips.

The S&P/ASX 200 Index (ASX: XJO) rose 0.9% last week in a positive start to the new financial year. 

In FY26, ASX 200 shares put in a respectable performance, lifting 2.8% and delivering total returns of 7%.   

Here, we look at three ASX 200 shares that the experts have a bullish view on for FY27.  

Zip Co Ltd (ASX: ZIP)

The Zip share price rose 5.5% to close out FY26 at $3.24 on 30 June.  

Jonathon Higgins from United Capital Partners (UCPS) has a buy rating on this ASX 200 buy now, pay later share for FY27.

Higgins considers Zip’s turnaround over the past few years as one of the best he’s ever witnessed. 

In a new note, Higgins points out that Zip is on track to report annual cash earnings of more than $260 million just three years after a $50 million cash earnings loss. 

Back then, Zip abandoned its plans for global expansion to instead focus on its core markets of Australia and the US.

Today, Higgins reckons the market is underappreciating Zip’s cost discipline and its prospects for further growth in the US. 

Compared to US-listed BNPL peers, Higgins says Zip shares are the cheapest and could be in for a re-rate in FY27.

UCPS has a buy rating on Zip with a target share price of $4.85. This implies a potential 50% upside over the next 12 months. 

Higgins commented: 

Sustainable earnings momentum against structural growth is hard to find on the ASX currently. 

Resmed CDI (ASX: RMD)

The Resmed share price fell 26.6% to $28.88 on 30 June amid a broader healthcare sector downturn in FY26. 

Blake Halligan from Catapult Wealth has a buy rating on this ASX 200 healthcare share. 

Halligan explained (courtesy The Bull): 

ResMed is a global leader in sleep apnoea devices and digital health platforms, benefiting from strong structural demand and resilient clinical positioning.

Despite the progression in GLP-1 therapies for treating sleep apnoea, ResMed’s CPAP (continuous positive airway pressure) treatments remain superior at this point in time.

RMD continues to offer appealing growth, income and defensive healthcare exposure.

QBE Insurance Group Ltd (ASX: QBE) 

The QBE share price lifted 7.7% in FY26 to close the year at $25.19. 

In an article, fund manager Market Partners described QBE as one of the most compelling artificial intelligence (AI) cost-reduction stories on the ASX.  

The QBE share price has been on a tear since the insurer reported a 21% increase in net profit after tax (NPAT) for FY25 in February.

QBE shares hit a multi-year high of $25.32 on the first day of the new financial year. 

Gerrish explained their bullish view on the ASX 200 financial share in a recent webinar: 

They’ve been working hard over the last five, 10 years around simplification of their business.

So they went out there, they made a huge number of acquisitions… and it’s starting to pay benefits.

The experts said QBE was an emerging turnaround story, with the share price now trading at 15-year highs.

Gerrish added:

Turnarounds can take a lot longer than anyone envisages.

But once a turnaround is starting to gain traction like it is in QBE, then the stock can run a lot further and a lot longer than anyone thinks.

So, on 12x [P/E], growing earnings at high single digits, yielding 4.7% part-franked [dividends] with earnings tailwinds, we think QBE stacks up.

 

The post 3 ASX 200 shares to buy now: experts appeared first on The Motley Fool Australia.

Should you invest $1,000 in QBE Insurance right now?

Before you buy QBE Insurance shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and QBE Insurance wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 16 June 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Bronwyn Allen has positions in Zip Co. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts